2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162759
    Sigma-1 receptor antagonist 6 1335032-28-4 98%
    Sigma-1 receptor antagonist 6 (Compound 12) is an antagonist of the Sigma-1 receptor (σ1R). Sigma-1 receptor antagonist 6 exerts a robust antiallodynic effect by antagonizing σ1R. Sigma-1 receptor antagonist 6 can be used in neuropathic pain animal models to alleviate mechanical allodynia induced by paclitaxel (HY-B0015).
    Sigma-1 receptor antagonist 6
  • HY-162760
    COMT-IN-1 2987884-27-3 98%
    COMT-IN-1 (compound C12), a nitrophenolic analogue, is an orally active dopamine metabolic enzyme catechol-O-methyltransferase (COMT) inhibitor with IC50s of 0.37 μM, 95.58 μM and 58.82 μM for COMT, MAO-A and MAO-B, respectively. COMT-IN-1 exhibits chelation with a variety of metal ions. COMT-IN-1 exhibits good BBB permeability. COMT-IN-1 improves dopamine levels and ameliorates MPTP (HY-15608)-induced Parkinson's disease (PD) symptoms in mice.
    COMT-IN-1
  • HY-162767
    KUNG65 2144469-30-5 98%
    KUNG65 is a selective inhibitor of Grp94, with a target Kd of 540 nM and at least 73 fold selectivity vs. the other Hsp90 isoforms.
    KUNG65
  • HY-162771
    Mu opioid receptor agonist 1 98%
    Mu opioid receptor agonist 1 (compound 12) is a Mu opioid receptor agonist. Mu opioid receptor agonist 1 can be used in nervous system related research.
    Mu opioid receptor agonist 1
  • HY-162786
    Nurr1 agonist 11 1090335-04-8 98%
    Nurr1 agonist 11 (compound 53) is a selective and potent Nurr1 agonist with an IC50 of 26 µM. Nurr1 agonist 11 has the ability to cross a cellular model of the blood-brain-barrier (BBB) .
    Nurr1 agonist 11
  • HY-162812
    H3R antagonist 4 98%
    H3R antagonist 4 (compound 11L) was a dual inhibitor of cholinesterase and histamine receptor (H3R), with corresponding IC50 of 7.04 μM (eeAChE), 9.73 μM (hAChE)(reversible) and 1.09 nM (H3R) , respectively. H3R antagonist 4 inhibited the aggregation of Aβ1-42 induced by itself and Cu2+ (95.48% and 88.63%) , and degraded the Aβ1-42 fibrils induced by itself and Cu2+ (80.16% and 89.30%) . H3R antagonist 4 chelate biometals such as Cu2+, Zn2+, Al3+, and Fe2+. H3R antagonist 4 significantly reduced tau protein hyperphosphorylation induced by Aβ1-42 and inhibited RSL-3-induced apoptosis and ferroptosis in PC12 cells. H3R antagonist 4 had the best blood-brain barrier permeability and intestinal absorption in hCMEC/D3 and hPepT1-MDCK cells.H3R antagonist 4 ameliorates learning and memory impairment in a mouse model of Alzheimer's disease induced by scopolamine (HY-N0296) .
    H3R antagonist 4
  • HY-162821
    LI-3948 3024591-38-3 98%
    IP6K-IN-2 (compound 29c) is an orally bioavailable and blood-brain barrier permeable IP6K inhibitor (IC50: 15.8 nM) that can be used in the study of central nervous system diseases.
    LI-3948
  • HY-162830
    5-LOX/MAOs-IN-1 33865-93-9 98%
    5-LOX/MAOs-IN-1 (compound 3) is a 5-LOX/MAOs inhibitor and a potent free radical scavenger with antioxidant properties. 5-LOX/MAOs-IN-1 also showed neuroprotective activity in oxidative stress-damaged cell models and can activate the neurogenesis microenvironment of adult mouse neural stem cells. 5-LOX/MAOs-IN-1 can be used for the study of neurodegenerative diseases.
    5-LOX/MAOs-IN-1
  • HY-162832
    Amyloid-β-IN-1 98%
    Amyloid-β-IN-1 (compound 13) is a synthetic peptide containing the hydrophobic C-terminal region "VVIA-NH2" and its reverse sequence "AIVV-NH2" of Aβ42, which is an Aβ inhibitor. Amyloid-β-IN-1 can inhibit Aβ aggregation and has neuroprotective effects.
    Amyloid-β-IN-1
  • HY-162850
    DOR agonist 2 1212540-02-7 98%
    DOR agonist 2 (Compound 3) is a Delta Opioid Receptor agonist. DOR agonist 2 can inhibit the expression of TNF-α, prevent NF-κB transport to the nucleus, and activate the G protein-mediated ERK1/2 pathway. DOR agonist 2 can be used in the study of neurodegenerative diseases.
    DOR agonist 2
  • HY-162856
    TRPV1-IN-2 98%
    TRPV1-IN-2 ((R)-32) is a TRPV1 inhibitor. TRPV1-IN-2 has protective effects on ED epilepsy models.
    TRPV1-IN-2
  • HY-162857
    Heme Oxygenase-1-IN-3 1043712-39-5 98%
    Heme Oxygenase-1-IN-3 (compound 4) is a highly selective heme oxygenase-1 (HO-1) inhibitor (Kd=141 nM) that can be used in the research of cancer and neurodegenerative diseases.
    Heme Oxygenase-1-IN-3
  • HY-162860
    FO-4-15 1030759-58-0 98%
    FO-4-15 is an mGluR1/CaMKIIα activator. FO-4-15 has a protective effect against H2O2 in human neuroblastoma (SH-SY5Y) cells. FO-4-15 can improve cognitive impairment in Alzheimer’s disease mice by activating the mGluR1/CaMKIIα pathway, and can reduce Aβ accumulation, hyperphosphorylated Tau, and synaptic damage.
    FO-4-15
  • HY-162908
    TRPV1/CB2 agonist 1 98%
    TRPV1/CB2 agonist 1 (compound 41) is a TRPV1/CB2 agonist, with an EC50 of 26.8 μM for hTRPV1. TRPV1/CB2 agonist 1 can be used in nervous system related research.
    TRPV1/CB2 agonist 1
  • HY-162913
    GSK-3β inhibitor 20 3044109-48-7 98%
    GSK-3β inhibitor 20 (compound 3A) is an potent inhibitor of GSK-3β with an IC50 value of 74.4 nM.
    GSK-3β inhibitor 20
  • HY-162915
    AChE-IN-75 98%
    AChE-IN-75 (N-(2′-methyl)allylnorgalanthamine) is an AChE inhibitor. AChE-IN-75 can be used in Alzheimer's disease research.
    AChE-IN-75
  • HY-162916
    AChE-IN-76 98%
    AChE-IN-76 (compound 6) is an inhibitor of acetylcholinesterase with an IC50 value of 7.6 nM.
    AChE-IN-76
  • HY-162922
    MAP4K4-IN-6 98%
    MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor (IC50: 80 nM). MAP4K4-IN-6 reduces the c-Jun phosphorylation. MAP4K4-IN-6 has neuroprotective effects. MAP4K4-IN-6 increases the viability of motor neurons. MAP4K4-IN-6 can be used for research of Amyotrophic lateral sclerosis (ALS).
    MAP4K4-IN-6
  • HY-162925
    CGRP antagonist 6 98%
    CGRP antagonist 6 (Compound 23) is a CGRP receptor antagonist (Ki: 0.84 nM). CGRP antagonist 6 can be used for research of migraine.
    CGRP antagonist 6
  • HY-162928
    RIPK1-IN-26 2252271-96-6 98%
    RIPK1-IN-26 (Compound 8a) is a potent receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with cell anti-necroptosis potency. RIPK1-IN-26 demonstrats good metabolic stability and good binding specificity in mice. RIPK1-IN-26 is promising for research of PET imaging probe development and neurodegenerative disorders.
    RIPK1-IN-26
Cat. No. Product Name / Synonyms Application Reactivity